Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 receptor inhibitor is the
standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several …

Introduction Over the course of 2021, numerous key clinical trials with valuable contributions
to clinical cardiology were published or presented at major international conferences. This …

Background It remains unclear whether clopidogrel is better suited than aspirin as the long-
term antiplatelet monotherapy following dual antiplatelet therapy (DAPT) after percutaneous …

Background: We conducted a systematic review and meta-analysis to examine the feasibility
of paclitaxel-coated balloon (PCB) angioplasty for de novo lesions in patients with acute …

Antiplatelet therapy (APT) is the foundation of treatment and prevention of atherothrombotic
events in patients with atherosclerotic cardiovascular disease. Selecting the optimal APT …

Background Among patients treated with a novel oral anticoagulant (NOAC) undergoing
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …

The principal goals of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) are prevention of stent thrombosis and, in those treated for acute coronary …

Background and aims High bleeding risk (HBR) and acute coronary syndrome (ACS)
subtypes are critical in determining bleeding and cardiovascular event risk after …

Background: The safety and feasibility of using 1-month dual antiplatelet therapy (DAPT)
followed by P2Y 12 inhibitor monotherapy for patients after percutaneous coronary …

Dual antiplatelet therapy—the combination of aspirin and a P2Y12 inhibitor—remains the
standard antiplatelet regimen recommended to prevent ischemic complications immediately …